

Personal Information

Email: deniz.can.guven@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/deniz.can.guven>

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study**
Kahraman S., Hizal M., Demirel B. C., GÜVEN D. C., GÜMÜŞAY Ö., OYAN ULUÇ B., BAYRAM E., Gulbagci B., YAŞAR A., Davarci S. E., et al.
BMC CANCER, vol.24, no.1, 2024 (SCI-Expanded)
- II. **Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis**
Vitale E., Rizzo A., Maistrello L., GÜVEN D. C., Massafra R., Mollica V., Monteiro F. S. M., Santoni M., Massari F.
SCIENTIFIC REPORTS, vol.14, no.1, 2024 (SCI-Expanded)
- III. **Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer**
YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., Chalabiyev E., AKTAŞ B. Y., ARIK Z., ERMAN M.
BMC CANCER, vol.24, no.1, 2024 (SCI-Expanded)
- IV. **Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers-Based Model**
Comes M. C., Fanizzi A., Bove S., Boldrini L., Latorre A., GÜVEN D. C., Iacovelli S., Talenti T., Rizzo A., Zito F. A., et al.
CANCER MEDICINE, vol.13, no.24, 2024 (SCI-Expanded)
- V. **Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer**
AKYILDIZ A., Ismayilov R., Abdurrahimli N., Ormanci A., GÜVEN D. C., TUNCEL M., ONUR M. R., Askoy S.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024 (SCI-Expanded)
- VI. **Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma**
Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., Kapar C., UZUN M., Perkin P., Akgul F., et al.
JOURNAL OF CHEMOTHERAPY, 2024 (SCI-Expanded)
- VII. **Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)**
AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., Aslan F., SÜTCÜOĞLU O., YAZICI O., Kadioglu A., et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, vol.281, no.9, pp.4991-4999, 2024 (SCI-Expanded)
- VIII. **Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab**
YILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., Ceyhan F., Kavruk O., GÜVEN D. C., Ates O., et al.
BIOMOLECULES AND BIOMEDICINE, vol.24, no.4, pp.998-1003, 2024 (SCI-Expanded)
- IX. **The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer**

YILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., Chalabiyev E., Yilmaz F., Yildirim S. S., KUŞ F., et al.
MEDICINE, vol.103, no.30, 2024 (SCI-Expanded)

- X. **Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors**
KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., AKSOY S., ERMAN M., YALÇIN Ş.
SUPPORTIVE CARE IN CANCER, vol.32, no.7, 2024 (SCI-Expanded)
- XI. **Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine**
ŞAHİN T. K., AKYILDIZ A., DOĞAN O. T., KAVGACI G., GÜVEN D. C., AKSOY S.
PHARMACEUTICALS, vol.17, no.7, 2024 (SCI-Expanded)
- XII. **Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis**
Sahin T. K., Rizzo A., AKSOY S., Guven D. C.
CANCERS, vol.16, no.10, 2024 (SCI-Expanded)
- XIII. **The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review**
GÜVEN D. C., KAVGACI G., ERUL E., Syed M. P., Magge T., Saeed A., YALÇIN Ş., Sahin I. H.
ONCOLOGIST, vol.29, 2024 (SCI-Expanded)
- XIV. **Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer**
Schipilliti F. M., Drittone D., Mazzuca F., La Forgia D., GÜVEN D. C., Rizzo A.
Heliyon, vol.10, no.7, 2024 (SCI-Expanded)
- XV. **The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis**
Guven D. C., Sahin T. K.
Breast Cancer Research and Treatment, vol.204, no.3, pp.443-452, 2024 (SCI-Expanded)
- XVI. **The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study**
Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., Şakalar T., Celayir Ö. M., KAYIKÇIOĞLU E., Aslan F., et al.
International Journal of Clinical Oncology, vol.29, no.3, pp.258-265, 2024 (SCI-Expanded)
- XVII. **Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer**
Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., Ersoy M., Guven D. C., Erturk I., Durmus Y., Karacin P., et al.
Future oncology (London, England), vol.20, no.4, pp.207-214, 2024 (SCI-Expanded)
- XVIII. **Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes**
Rizzo A., Rinaldi L., Massafra R., Cusmai A., GÜVEN D. C., Forgia D. L., Latorre A., Giotta F.
FUTURE ONCOLOGY, vol.20, no.20, pp.1427-1434, 2024 (SCI-Expanded)
- XIX. **Editorial: Advances in the treatment of hormonal receptor positive (HR plus) breast cancer**
Ben Kridis W., Wang Z., GÜVEN D. C., Dharmarajan A.
FRONTIERS IN ONCOLOGY, vol.14, 2024 (SCI-Expanded)
- XX. **The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study**
Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvacı K., DURSUN B., Celayir M., Chelebiyev E., Nayir E., ERMAN M., et al.
Cancer Medicine, vol.13, no.1, 2024 (SCI-Expanded)
- XXI. **Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review**
GÜVEN D. C., Thong M. S., Arndt V.
Journal of Cancer Survivorship, 2024 (SCI-Expanded)
- XXII. **Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)**

BİLGİN E., Demirci Yıldırım T., Özdemir Ulusoy B., Ögüt T. S., Karabacak M., Sadioğlu Çağdaş Ö., YILDIRIM R., Güven D. C., Akleylek C., Ediboğlu E., et al.

Internal and Emergency Medicine, 2024 (SCI-Expanded)

- XXIII. **Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors**
Laface C., Fina E., Ricci A. D., GÜVEN D. C., Ambrogio F., De Summa S., Vitale E., Massafra R., Brunetti O., Rizzo A.
EXPERT OPINION ON BIOLOGICAL THERAPY, vol.24, pp.1363-1374, 2024 (SCI-Expanded)
- XXIV. **Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study**
Karadurmus N., Kaplan M. A., Sendur M. A. N., ÜRÜN Y., Demirci U., Karaca S. B., Aydın S. G., Aykan M. B., Bilici A., Sezer A., et al.
CURRENT MEDICAL RESEARCH AND OPINION, vol.40, pp.1171-1178, 2024 (SCI-Expanded)
- XXV. **Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy**
Sahin T. K., ÖZBAY Y., ALTUNBULAK A. Y., ALTUNBULAK H. İ., ONUR M. R., Ceylan F., GÜVEN D. C., YALÇIN Ş., DİZDAR Ö.
International Journal of Clinical Oncology, 2024 (SCI-Expanded)
- XXVI. **Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis**
GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., AKSOY S.
Laryngoscope, vol.134, no.1, pp.7-17, 2024 (SCI-Expanded)
- XXVII. **The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study**
KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., Chalabiyev E., AKYILDIZ A., KÖKSAL B., ŞAHİN Y. B., et al.
INTEGRATIVE CANCER THERAPIES, vol.23, 2024 (SCI-Expanded)
- XXVIII. **The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing**
KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündoğdu A., Sever N., Ayhan M., Çelebi A., Majidova N., et al.
Journal of Chemotherapy, 2024 (SCI-Expanded)
- XXIX. **Sunitinib experience in adult patients with vascular malformations**
AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., Chalabiyev E., TÜRKER F. A., DİZDAR Ö., YALÇIN Ş., et al.
Vascular, 2024 (SCI-Expanded)
- XXX. **Comparison between vision transformers and convolutional neural networks to predict non-small lung cancer recurrence**
Fanizzi A., Fadda F., Comes M. C., Bove S., Catino A., Di Benedetto E., Milella A., Montrone M., Nardone A., Soranno C., et al.
Scientific Reports, vol.13, no.1, 2023 (SCI-Expanded)
- XXXI. **A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology**
YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.
Irish Journal of Medical Science, vol.192, no.6, pp.2631-2634, 2023 (SCI-Expanded)
- XXXII. **The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey**
AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., YILDIZ İ., Iriagac Y., Turhal S., Akbas S., et al.
Medicine, vol.102, no.45, 2023 (SCI-Expanded)
- XXXIII. **A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer**

- YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., YALÇIN Ş.
Anti-cancer drugs, vol.34, no.10, pp.1190-1192, 2023 (SCI-Expanded)
- XXXIV. **Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia**
AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., GÜNER G., GÜVEN D. C., ARIK Z., KERTMEN N., et al.
Current Oncology, vol.30, no.11, pp.9689-9700, 2023 (SCI-Expanded)
- XXXV. **Looking at FOxTROT Through the Lens of IDEA**
GÜVEN D. C.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.41, no.30, pp.4821-4822, 2023 (SCI-Expanded)
- XXXVI. **Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer**
Şener G. Y., SÜTCÜOĞLU O., ÖĞÜT B., GÜVEN D. C., KAVUNCUOĞLU A., ÖZDEMİR N., ÖZET A., AKSOY S., Tezel Y. G. G., Akyürek N., et al.
Strahlentherapie und Onkologie, vol.199, no.8, pp.761-772, 2023 (SCI-Expanded)
- XXXVII. **Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives**
ERUL E., GÜVEN D. C., ONUR M. R., YAZICI G., AKSOY S.
European Archives of Oto-Rhino-Laryngology, vol.280, no.8, pp.3541-3556, 2023 (SCI-Expanded)
- XXXVIII. **The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study**
GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., AKSOY S., ERMAN M., YALÇIN Ş., ÜRÜN Y., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.149, no.7, pp.3599-3606, 2023 (SCI-Expanded)
- XXXIX. **The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors**
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., YILDIRIM H. Ç., Chalabiyev E., Cebroyilov C., YILDIRIM T., et al.
Anti-Cancer Drugs, vol.34, no.6, pp.783-790, 2023 (SCI-Expanded)
- XL. **The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)**
Hızal M., Bilgin B., Paksoy N., Atci M. M., KAHRAMAN S., Kilickap S., GÜVEN D. C., KESKİNKILIÇ M., Ayhan M., Eren O., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.149, no.8, pp.4141-4148, 2023 (SCI-Expanded)
- XLI. **SMART syndrome: a case report**
Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., Oguz K. K., DİZDAR Ö.
ACTA NEUROLOGICA BELGICA, vol.123, no.3, pp.1137-1140, 2023 (SCI-Expanded)
- XLII. **Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort**
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., Chalabiyev E., KUŞ F., YALÇIN Ş., AKSOY S.
Medicine (United States), vol.102, no.18, 2023 (SCI-Expanded)
- XLIII. **The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma**
GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., Kaygusuz Y., ÇAYIRÖZ K., ÜÇDAL M. T., Yesil F., et al.
European Archives of Oto-Rhino-Laryngology, vol.280, no.5, pp.2471-2478, 2023 (SCI-Expanded)
- XLIV. **Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer**
Kahraman S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., Acar O., AKSOY S., Baytemur N. K., ŞAHİN E., et al.

Future oncology (London, England), vol.19, no.10, pp.727-736, 2023 (SCI-Expanded)

- XLV. **Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer**
Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., Turker A., Hamaloglu E., KARAKOÇ D., Isik A., et al.
Clinics and Research in Hepatology and Gastroenterology, vol.47, no.3, 2023 (SCI-Expanded)
- XLVI. **Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer**
Akagunduz B., Guven D. C., Ozer M., Okten I. N., Atag E., Unek İ. T., TATLI A. M., Karaoglu A.
Journal of Geriatric Oncology, vol.14, no.2, 2023 (SCI-Expanded)
- XLVII. **Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy**
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., YÜCE D., ARIK Z., KILIÇKAP S., AKSOY S., et al.
INTERNATIONAL JOURNAL OF CANCER, vol.152, pp.679-685, 2023 (SCI-Expanded)
- XLVIII. **Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment**
Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., AKSOY S.
Expert Review of Anticancer Therapy, vol.23, no.10, pp.1049-1059, 2023 (SCI-Expanded)
- XLIX. **Emerging treatment strategies in hepatobiliary cancer**
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., AKYILDIZ A., AKTAŞ B. Y., YALÇIN Ş., DİZDAR Ö.
Expert Review of Anticancer Therapy, vol.23, no.3, pp.243-256, 2023 (SCI-Expanded)
- L. **The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis**
GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., YALÇIN Ş.
Frontiers in Molecular Biosciences, vol.9, 2022 (SCI-Expanded)
- LI. **Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards**
GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., ARIK Z., DİZDAR Ö., ÜNAL S., METAN G., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.8, pp.1807-1811, 2022 (SCI-Expanded)
- LII. **Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study**
YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., Celebi A., DURSUN B., Acar O., KAHRAMAN S., et al.
BREAST, vol.66, pp.85-88, 2022 (SCI-Expanded)
- LIII. **Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group**
Gurbuz M., Kutlu Y., AKKUŞ E., KÖKSOY E. B., Kose N., Oven B. B., Uluc B. O., Demiray A. G., Erdem D., Demir B., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded)
- LIV. **Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis**
BAŞ O., Erul E., GÜVEN D. C., AKSOY S.
SUPPORTIVE CARE IN CANCER, vol.30, no.11, pp.9071-9078, 2022 (SCI-Expanded)
- LV. **SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research**
GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.
ONCOLOGIST, vol.27, no.11, 2022 (SCI-Expanded)
- LVI. **Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine**
Carloni R., Rizzo A., Ricci A. D., Di Federico A., De Luca R., GÜVEN D. C., YALÇIN Ş., Brandi G.

TRANSLATIONAL ONCOLOGY, vol.25, 2022 (SCI-Expanded)

- LVII. **The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges**
GÜVEN D. C., ŞAHİN T. K., Rizzo A., Ricci A. D., AKSOY S., ŞAHİN K.
APPLIED SCIENCES-BASEL, vol.12, no.20, 2022 (SCI-Expanded)
- LVIII. **Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease**
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKSOY S., ERMAN M., KILIÇKAP S., YALÇIN Ş.
JOURNAL OF CLINICAL MEDICINE, vol.11, no.17, 2022 (SCI-Expanded)
- LIX. **The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy**
GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., AKTEPE O. H., ERMAN M., KILIÇKAP S., AKSOY S., et al.
JOURNAL OF CLINICAL MEDICINE, vol.11, no.15, 2022 (SCI-Expanded)
- LX. **Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis**
Rizzo A., Carloni R., Ricci A. D., Di Federico A., GÜVEN D. C., YALÇIN Ş., Brandi G.
JOURNAL OF PERSONALIZED MEDICINE, vol.12, no.8, 2022 (SCI-Expanded)
- LXI. **The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study**
Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., Ak N., Yucel S., Ayhan M., EROL C., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.148, no.6, pp.1501-1508, 2022 (SCI-Expanded)
- LXII. **The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials**
GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., Erul E., AKSOY S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.174, 2022 (SCI-Expanded)
- LXIII. **Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.**
Güven D. C., Sayegh N., Tripathi N., Erman M., Agarwal N., Swami U.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16, 2022 (SCI-Expanded)
- LXIV. **The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy**
GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., ERMAN M., KILIÇKAP S., YALÇIN Ş.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.4, pp.785-793, 2022 (SCI-Expanded)
- LXV. **The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis**
GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S.
CANCERS, vol.14, no.11, 2022 (SCI-Expanded)
- LXVI. **Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination**
GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.
ONCOLOGIST, vol.27, 2022 (SCI-Expanded)
- LXVII. **HER2-low breast cancer could be associated with an increased risk of brain metastasis**
GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., KERTMEN N., DİZDAR Ö., ÜNER A., AKSOY S.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.27, no.2, pp.332-339, 2022 (SCI-Expanded)
- LXVIII. **Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma**
Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., İnci B. K., ARIK Z., YALÇIN Ş., ÖZDEMİR N., ÖZET A., YAZICI O.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.5, pp.1559-1568, 2022 (SCI-Expanded)
- LXIX. **The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a**

real-life study

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., KERTMEN N., DİZDAR Ö., AKSOY S.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.5, pp.1551-1558, 2022 (SCI-Expanded)

- LXX. **Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience**
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., GÜVEN D. C., Olgun P., KERTMEN N., DİZDAR Ö., et al.
FUTURE ONCOLOGY, vol.18, pp.323-331, 2022 (SCI-Expanded)
- LXXI. **Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment**
GÜRLER F., İlhan A., GÜVEN D. C., TURHAN O., KURT İNCİ B., SÜTCÜOĞLU O., Yildiz F., ARIK Z., Oksuzoglu B., YALÇIN Ş., et al.
ANTI-CANCER DRUGS, vol.33, no.1, 2022 (SCI-Expanded)
- LXXII. **A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer**
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.168, 2021 (SCI-Expanded)
- LXXIII. **Thirty-day mortality rates after immunotherapy initiation**
SÜTCÜOĞLU O., İlhan A., Tacar S. Y., GÜVEN D. C., Ucar G., Karadurmus N., Yildiz F., Eraslan E., Uncu D., Tural D., et al.
IMMUNOTHERAPY, vol.13, pp.1419-1426, 2021 (SCI-Expanded)
- LXXIV. **Assessment of abuse and related factors in older patients with cancer**
Akagunduz B., Altin Z., Atci M. M., Ozer M., GÜVEN D. C., Cil I., Ozcicek F., Demirtas L., Duzgun E., Gunderci A., et al.
SUPPORTIVE CARE IN CANCER, vol.29, no.12, pp.7957-7964, 2021 (SCI-Expanded)
- LXXV. **The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study**
GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., Ceylan F., ŞENDUR M. A. N., Demirci U., ÜRÜN Y., et al.
CURRENT PROBLEMS IN CANCER, vol.45, no.6, 2021 (SCI-Expanded)
- LXXVI. **Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats**
AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., ÖZERCAN İ. H., DİZDAR Ö., YALÇIN Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.12, pp.1049-1056, 2021 (SCI-Expanded)
- LXXVII. **The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme**
GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.
FUTURE ONCOLOGY, vol.17, pp.4405-4413, 2021 (SCI-Expanded)
- LXXVIII. **Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review**
GÜVEN D. C., ŞAHİN T. K., KILIÇKAP S., Uckun F. M.
FRONTIERS IN ONCOLOGY, vol.11, 2021 (SCI-Expanded)
- LXXIX. **The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy**
AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEKİN B., Yeter H. H., YÜCE D., DİZDAR Ö., ERMAN M.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.73, no.10, pp.1957-1963, 2021 (SCI-Expanded)
- LXXX. **Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality**
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., İncesu F. G. G., TAHILLIOĞLU Y., ÜÇGÜL E., AKSUN M. S., GÜRBÜZ S. Ç., AKTEPE O. H., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)
- LXXXI. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.
SUPPORTIVE CARE IN CANCER, vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded)

- LXXXII. **Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors**
GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., ŞAHİN T. K., AKSUN M. S., DİZDAR Ö., AKSOY S., et al.
BIOMARKERS IN MEDICINE, vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded)
- LXXXIII. **Sarcopenia and anthracycline cardiotoxicity in patients with cancer**
BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., BARIŞTA İ., GÜNER G., GÜVEN D. C., KERTMEN N., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (SCI-Expanded)
- LXXXIV. **Neoadjuvant capecitabine in rectal cancer chemoradiotherapy: too early to ring the alarms**
GÜVEN D. C., YALÇIN Ş.
INTERNAL MEDICINE JOURNAL, vol.51, no.8, pp.1365-1366, 2021 (SCI-Expanded)
- LXXXV. **Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report**
GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.5, pp.1281-1283, 2021 (SCI-Expanded)
- LXXXVI. **Reassurance of patients with cancer on cancer care continuum: a vital strategy to prevent anxiety of COVID-19 collateral damage**
GÜVEN D. C.
SUPPORTIVE CARE IN CANCER, vol.29, pp.3423-3424, 2021 (SCI-Expanded)
- LXXXVII. **A novel agnostic tumor: NTRKoma**
Ayasun R., GÜVEN D. C., Gullu İ. H.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.4, pp.802-803, 2021 (SCI-Expanded)
- LXXXVIII. **THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY**
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebayilov C., YILDIRIM T., DİZDAR Ö., AKSOY S., KILIÇKAP S., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.36, 2021 (SCI-Expanded)
- LXXXIX. **The relation between inflammation-based parameters and survival in metastatic pancreatic cancer**
Turker S., Cilbir E., GÜVEN D. C., Karacin C., YALÇIN Ş.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.17, no.2, pp.510-515, 2021 (SCI-Expanded)
- XC. **Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors**
GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., AKKAŞ M., ERMAN M., KILIÇKAP S., DİZDAR Ö., et al.
SUPPORTIVE CARE IN CANCER, vol.29, no.4, pp.2029-2035, 2021 (SCI-Expanded)
- XC. **Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience**
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., TABAN H., GÜVEN D. C., KERTMEN N., Oksuzoglu B., et al.
CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)
- XCII. **The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters**
GÜVEN D. C., ŞAHİN T. K., AKSOY S.
BREAST JOURNAL, vol.26, no.12, pp.2435-2436, 2020 (SCI-Expanded)
- XCIII. **Cancer incidence in Behcet's disease**
GÜVEN D. C., BÖLEK E. Ç., ALTINTOP S. E., ÇELİKTEK B., AKTAŞ B. Y., KIRAZ S., Gullu İ. H., KARADAĞ Ö., DİZDAR Ö.
IRISH JOURNAL OF MEDICAL SCIENCE, vol.189, no.4, pp.1209-1214, 2020 (SCI-Expanded)
- XCIV. **Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)**
Alkan A., Yasar A., Guc Z. G., Gurbuz M., BAŞOĞLU TÜYLÜ T., SEZGİN GÖKSU S., Basal F. B., TÜRK H. M., Ozdemir O., Cinkir H. Y., et al.
EUROPEAN JOURNAL OF CANCER CARE, vol.29, no.6, 2020 (SCI-Expanded)
- XC. **Effects of adenosine triphosphate on vandetanib induced skin damage in rats**
Akagunduz B., ÖZÇİÇEK F., Kara A. V., GÜVEN D. C., YAZICI G. N., Coban A., SÜLEYMAN B., MAMMADOV R.,

SÜLEYMAN H.

CUTANEOUS AND OCULAR TOXICOLOGY, vol.39, no.4, pp.323-327, 2020 (SCI-Expanded)

- XCVI. **Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design**
GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.
CLINICAL COLORECTAL CANCER, vol.19, no.3, 2020 (SCI-Expanded)
- XCVII. **All Positives May Not Be the Same in Pancreatic Cancer Lessons Learned From the Past**
Ceylan F., GÜVEN D. C., ŞAHİN T. K., ÖZBEK D. A., DİZDAR Ö.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.43, no.9, pp.676, 2020 (SCI-Expanded)
- XCVIII. **Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19**
GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S.
FRONTIERS IN ONCOLOGY, vol.10, 2020 (SCI-Expanded)
- XCIX. **Cancer incidence in Behcet's Disease.**
Güven D. C., Bolek E. C., Altıntop S. E., Celikten B., Aktas B. Y., Kiraz S., Gullu I. H., Karadag O., Dizdar O.
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (SCI-Expanded)
- C. **Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications**
GÜVEN D. C., AKTAŞ B. Y., ŞİMŞEK C., AKSOY S.
FUTURE ONCOLOGY, vol.16, no.9, pp.497-506, 2020 (SCI-Expanded)
- CI. **Complete responses to two different anti-PD1 agents in a metastatic melanoma patient**
KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.2, pp.496-499, 2020 (SCI-Expanded)
- CII. **Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer**
GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.1, pp.256-258, 2020 (SCI-Expanded)
- CIII. **Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study**
Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., Yilmaz M., Meydanli M. M., Oksuzoglu B.
JOURNAL OF BUON, vol.24, no.6, pp.2327-2332, 2019 (SCI-Expanded)
- CIV. **Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy**
AKTAŞ B. Y., Güner G., Guven D. C., Arslan C., DİZDAR Ö.
EXPERT REVIEW OF ANTICANCER THERAPY, vol.19, no.7, pp.589-601, 2019 (SCI-Expanded)
- CV. **Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia**
BİLGİN E., DİZDAR Ö., Guven D. C., Ceylan S., AYBI Ö., FIRLATAN B., KARDAŞ R. C., YILDIRIM T., Hayran M. K., KALYONCU U., et al.
Rheumatology International, vol.39, no.6, pp.1045-1051, 2019 (SCI-Expanded)
- CVI. **Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients**
Güven D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., Lacin S., Karakas Y., KILIÇKAP S., Hayran M., et al.
BIOMARKERS IN MEDICINE, vol.13, no.9, pp.725-735, 2019 (SCI-Expanded)
- CVII. **Evaluation of cancer risk in patients with periodontal diseases**
Güven D. C., DİZDAR Ö., AKMAN A. C., Berker E., Yekeduz E., Ceylan F., Baspinar B., Akbiyik I., AKTAŞ B. Y., YÜCE D., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.3, pp.826-831, 2019 (SCI-Expanded)
- CVIII. **A rare cause of proximal muscle weakness: immune necrotising myopathy**
GÜVEN D. C., ERDEN A., KILIÇ L., ERDEM ÖZDAMAR S., KARADAĞ Ö.
SCOTTISH MEDICAL JOURNAL, vol.63, no.3, pp.82-86, 2018 (SCI-Expanded)
- CIX. **Fusobacterium and colorectal carcinogenesis**
Güven D. C., DİZDAR Ö.
CARCINOGENESIS, vol.39, no.1, pp.84, 2018 (SCI-Expanded)
- CX. **Increased cancer risk in patients with periodontitis**

DİZDAR Ö., HAYRAN M., Guven D. C., YILMAZ T. B., TAHERI S., AKMAN A. C., BİLGİN E., HUSEYİN B., BERKER E.
CURRENT MEDICAL RESEARCH AND OPINION, vol.33, no.12, pp.2195-2200, 2017 (SCI-Expanded)

CXI. Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment

ATEŞ Ö., GÜVEN D. C., BABACAN T., Sunar V., Sarici F., AKSOY S., SEVER A. R., Ozisik Y., Altundag K.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.4, pp.206-214, 2016 (SCI-Expanded)

CXII. Fatigue May be Independently Active at a Certain Part of Spondyloarthritis Patients: Hur-BIO Real Life Results

KALYONCU U., Erden A., KILIÇ L., Seyhoglu E., Guven D. C., AKTAŞ B. Y., ŞENER Y. Z., KARADAĞ Ö., Bilgen S. A., AKDOĞAN A., et al.
ARTHRITIS & RHEUMATOLOGY, vol.67, 2015 (SCI-Expanded)

CXIII. Acute erythroid leukemia in a patient with chronic lymphocytic leukemia

GÜVEN D. C., BABACAN T., Sarici F., AKIN S., Altundag K., Turker A.
JOURNAL OF BUON, vol.19, no.4, pp.1127, 2014 (SCI-Expanded)

Articles Published in Other Journals

I. Prognostic impact of myosteatosi on survival with immune checkpoint inhibitors: A systematic review and meta-analysis

Sahin T. K., Guven D. C.
CLINICAL NUTRITION ESPEN, vol.63, pp.829-836, 2024 (ESCI)

II. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., AKSOY S., ERMAN M., YALÇIN Ş., Kilickap S.
Journal of Immunotherapy and Precision Oncology, vol.6, no.4, pp.170-176, 2023 (Scopus)

III. Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

EROL C., HAFIZOĞLU E., aykan m. b., GÜVEN D. C., Dursun B., Hizal M., kahraman s., sener dede d., Akinci M. B., Karadurmuş N., et al.
ACTA ONCOLOGICA TURCICA, vol.56, no.2, pp.170-179, 2023 (Peer-Reviewed Journal)

IV. Learning From Failure: Negative Trials in Oncology

Nardo M., GÜVEN D. C., Yikilmaz A. S., Singh S., Ahmed J.
Journal of Immunotherapy and Precision Oncology, vol.6, no.2, pp.59-60, 2023 (Scopus)

V. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., AKYILDIZ A., YILMAZ F., YAŞAR S., Evlendi Y., et al.
Journal of Oncological Science, vol.9, no.1, pp.33-37, 2023 (Scopus)

VI. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Erol C., Bardakçı M., Hizal M., Kahraman S., Yekedüz E., GÜVEN D. C., Aykan M. B., Ak R., Ateş Ö., ŞENER DEDE D., et al.
Journal of Oncological Science, vol.9, no.2, pp.72-78, 2023 (Scopus)

VII. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review

YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., AKIN S., YALÇIN Ş., BARIŞTA İ.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, vol.15, no.4, pp.307-310, 2022 (ESCI)

VIII. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report

TABAN H., GÜVEN D. C., Kilickap S.
CUREUS JOURNAL OF MEDICAL SCIENCE, vol.14, no.8, 2022 (ESCI)

IX. Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive

Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Gurbuz M., Akkus E., Sakin A., Urvay S., Demiray A. G., Sahin S., Sakalar T., EROL C., ŞENDUR M. A. N., ŞAHİN A. B., et al.

JOURNAL OF GASTROINTESTINAL CANCER, vol.53, no.2, pp.282-288, 2022 (ESCI)

- X. **Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy**
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKTAŞ B. Y., GÜNER G., DİZDAR Ö., AKSOY S., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI)
- XI. **Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy**
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., KUŞ F., AKYILDIZ A., GÜRBÜZ S. Ç., Sayin H., et al.
Journal of Oncological Science, vol.8, no.3, pp.143-147, 2022 (Scopus)
- XII. **Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review**
Yigit E., GÜVEN D. C., AKSOY S., YAZICI G.
CUREUS, vol.13, no.6, 2021 (ESCI)
- XIII. **Artificial intelligence method to predict overall survival of hepatocellular carcinoma**
ŞİMŞEK C., GÜVEN D. C., Sahin T. K., TEKİN İ. E., Sahan O., BALABAN H. Y., YALÇIN Ş.
Hepatology Forum, vol.2, no.2, pp.64-68, 2021 (Scopus)
- XIV. **Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma**
AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., Ardic F. S., Yeter H. H., YÜCE D., ERMAN M.
TURKISH JOURNAL OF UROLOGY, vol.47, no.2, pp.113-119, 2021 (ESCI)
- XV. **Thyroid gland metastasis mimicking thyroid carcinoma in a lung cancer patient and dramatic response to crizotinib: A case report**
Erul E., GÜVEN D. C., ŞAHİN T. K., Gullu İ. H.
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, vol.69, no.1, pp.98-101, 2021 (ESCI)
- XVI. **An Unusual Case of Tuberculosis Lenfadenitis Mimicking Tularemia**
Başpınar B., HELVACI Ö., GÜVEN D. C., İNKAYA A. Ç.
Turkiye Klinikleri Journal of Internal Medicine, vol.1, no.2, pp.111-113, 2016 (Peer-Reviewed Journal)

Books & Book Chapters

I. PATOFİZYOLOJİNİN TEMELLERİ

DURUSU TANRIÖVER M., SARI A., EŞME M., KOÇ YILDIRIM S., YILDIRIM M. Ş., BÖLEK E. Ç., YAVUZ SARI S. Ö., YEKEDÜZ E., GÜRLER F., KORKMAZ E. T., et al.
PALME YAYINCILIK, 2017

Refereed Congress / Symposium Publications in Proceedings

- I. **Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).**
Akyildiz A., Guven D. C., Koksall B., Karaoglan B. B., Salim D. K., Sutcuoglu O., Erciyestepe M., Alan O., Taban H., Yildirim N., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024
- II. **outcomes of patients with resected pancreatic ductal adenocarcinoma**

ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., KILIÇKAP S., YALÇIN Ş., DİZDAR Ö.
9th international gastrointestinal cancer conference, 6 - 08 December 2019

- III. **MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?**
BİLGİN E., GÜVEN D. C., Ceylan S., AYBI ÖZDEMİR Ö., KARDAŞ R. C., FIRLATAN B., YILDIRIM T., ÖZEN S., DİZDAR Ö., HAYRAN K. M., et al.
Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.993
- IV. **Clinical features and prognosis of patients with liposarcoma: Single-center experience.**
Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., Kilickap S., Kars A., Turker A., Yalcin S., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- V. **Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi**
GÜVEN D. C., ERGÜNAY K., BRİNKMANN A., ALP A., AKDOĞAN KITTANA F. N., AKYÖN YILMAZ Y., YILMAZ E., KARAKOÇ D., HAMALOĞLU E., YALÇIN Ş., et al.
2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018
- VI. **Metastatic Choroidal Melanoma: Single Center Experience**
AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., KILIÇKAP S., ÇELİK İ.
2. Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, pp.1-48
- VII. **Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorectal patients and healthy controls. Abst ID:"e15117"**
GÜVEN D. C., DİZDAR Ö., ALP A., Akdoğan Kittana F. N., KARAKOÇ D., Hamaloğlu E., LAÇİN Ş., KARAKAŞ Y., KILIÇKAP S., HAYRAN K. M., et al.
2018 ASCO, Chicago, United States Of America, 1 - 05 June 2018
- VIII. **Evaluation of cancer risk in patients with periodontal diseases.**
GÜVEN D. C., DİZDAR Ö., AKMAN A. C., BERKER A. E., YEKEDÜZ E., CEYLAN F., Baspınar B., AKBIYIK I., AKTAŞ B. Y., YÜCE D., et al.
2018 ASCO Annual Meeting, Chicago, United States Of America, 1 - 05 June 2018, vol.36, pp.13571
- IX. **Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis Analizi**
GÜVEN D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., LAÇİN Ş., KARAKAŞ Y., KILIÇKAP S., HAYRAN K. M., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- X. **SEVERE PERIODONTITIS IS ASSOCIATED WITH INCREASED CANCER RISK**
DİZDAR Ö., HAYRAN K. M., GÜVEN D. C., Yılmaz T. B., Taheri S., AKMAN A. C., BİLGİN E., Hüseyin B., BERKER A. E.
GAP 2017 Conference, Texas, United States Of America, 9 - 11 May 2017

Metrics

Publication: 140

Citation (WoS): 45

Citation (Scopus): 221

H-Index (WoS): 3

H-Index (Scopus): 9